Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
73 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2017, provides an overview of the Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) pipeline landscape. Juvenile macular degeneration is a series of inherited eye disorders that affects children and young adults. The most common form of juvenile macular degeneration is Stargardt disease. Stargardt's disease is an inherited autosomal recessive syndrome. Signs and symptoms include blurry or fuzzy vision, dark, empty spots in the center of vision and difficulty reading or performing detail work. Risk factors include arteriosclerosis, hypercholesterolemia, smoking and hypertension. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 5, 10 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively. Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology). - The pipeline guide reviews pipeline therapeutics for Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Juvenile Macular Degeneration (Stargardt Disease) - Overview Juvenile Macular Degeneration (Stargardt Disease) - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Juvenile Macular Degeneration (Stargardt Disease) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Juvenile Macular Degeneration (Stargardt Disease) - Companies Involved in Therapeutics Development Acucela Inc Alkeus Pharmaceuticals Inc Astellas Pharma Inc Copernicus Therapeutics Inc Grupo Ferrer Internacional SA Iris Pharma Nemus Bioscience Inc Ophthotech Corp ProQR Therapeutics NV Sanofi Juvenile Macular Degeneration (Stargardt Disease) - Drug Profiles ALK-001 - Drug Profile Product Description Mechanism Of Action R&D Progress ASP-7317 - Drug Profile Product Description Mechanism Of Action R&D Progress avacincaptad pegol sodium - Drug Profile Product Description Mechanism Of Action R&D Progress echothiophate iodide - Drug Profile Product Description Mechanism Of Action R&D Progress emixustat hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress FAB-111 - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy 1 to Activate ABCA4 for Stargardt Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy to Activate ABCA4 for Stargardt Disease - Drug Profile Product Description Mechanism Of Action R&D Progress LBS-008 - Drug Profile Product Description Mechanism Of Action R&D Progress NB-2222 - Drug Profile Product Description Mechanism Of Action R&D Progress Oligonucleotides to Activate ABCA4 for Stargardt Disease - Drug Profile Product Description Mechanism Of Action R&D Progress QRX-1011 - Drug Profile Product Description Mechanism Of Action R&D Progress ramiprilat - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Enzyme for Age Related Macular Degeneration and Stargardt Disease - Drug Profile Product Description Mechanism Of Action R&D Progress SAR-422459 - Drug Profile Product Description Mechanism Of Action R&D Progress soraprazan - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy for Ophthalmic Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress VM-200 - Drug Profile Product Description Mechanism Of Action R&D Progress Juvenile Macular Degeneration (Stargardt Disease) - Dormant Projects Juvenile Macular Degeneration (Stargardt Disease) - Product Development Milestones Featured News & Press Releases Jul 26, 2017: Ophthotech Expands Focus with Development for Ophthalmic Orphan Diseases, Provides Update on Zimura Jan 26, 2017: Acucela Initiates Phase 2a Study of Emixustat Hydrochloride Addressing Patients with Stargardt Disease Jan 05, 2017: Acucela Receives Orphan Drug Designation from the FDA for the Treatment of Stargardt Disease May 26, 2015: Ocata Therapeutics Receives Three New U.S. Patents for its RPE Therapy for Macular Degenerative Diseases May 04, 2015: European Medicines Agency Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease Mar 31, 2015: Ocata Therapeutics Successfully Completes Dosing in Phase 1/2 RPE Studies Oct 15, 2014: ACT Announces Positive Results from Two Clinical Trials Published in The Lancet Using Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells for the Treatment of Macular Degeneration Sep 25, 2014: Advanced Cell Technology Announces Final Patient Treated in Stargardt's Macular Degeneration Phase 1 Trial in the United Kingdom Jul 17, 2013: ACT Secures Approval from Data Safety Monitoring Board to Complete Third Patient Cohort in All Three Clinical Trials Jun 03, 2013: Oxford BioMedica Halts Recruitment Into Phase I/IIa Study Of StarGen May 16, 2013: ACT Confirms Clinical Trial Participant Shows Improvement In Vision Following Treatment With Human Embryonic Stem Cells Apr 23, 2013: ACT Initiates Higher-Dosage Patient Treatment In European Phase I Study For Macular Degeneration Apr 15, 2013: ACT Treats First Patient With Better Vision In Clinical Trial For Stargardt's Macular Dystrophy Apr 01, 2013: ACT Initiates Treatment Of Higher-dosage Cohort In Clinical Trials For Dry Age-related Macular Degeneration And Stargardt's Macular Dystrophy Mar 14, 2013: Advanced Cell Technology Receives DSMB Approval To Initiate Treatment Of Third Patient Cohort In All Three Clinical Trials Using hESC-derived RPE Cells Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Acucela Inc, H2 2017 Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Alkeus Pharmaceuticals Inc, H2 2017 Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Astellas Pharma Inc, H2 2017 Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Copernicus Therapeutics Inc, H2 2017 Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Grupo Ferrer Internacional SA, H2 2017 Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Iris Pharma, H2 2017 Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Nemus Bioscience Inc, H2 2017 Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Ophthotech Corp, H2 2017 Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by ProQR Therapeutics NV, H2 2017 Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Sanofi, H2 2017 Juvenile Macular Degeneration (Stargardt Disease) - Dormant Projects, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
